A phase II trial of weekly docetaxel and bortezomib (Velcade; PS-341) in the treatment of patients with advanced hormone-refractory prostate cancer
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2013
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Jul 2010 Actual end date (1 Feb 2007) added as reported by ClinicalTrials.gov.
- 27 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2005 New trial record.